AIDA project-events

ESCMID Conference on Reviving Old Antibiotics, Vienna, Austria 22 – 24 October 2014

In the face of increasing antimicrobial resistance and the lack of new agents it has become clear that we need new strategies. One of these must be to revisit old antibiotics to make sure that we are using them correctly and to their full potential as well as to find out if one or several of them can help alleviate the pressure on more recent agents. On 22.-24. October 2014, Vienna played host to a major expert conference, convened by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and scientifically organised by AIDA partners. International researchers, academics, representatives from pharmaceutical companies and national medical and regulatory agencies explored the potential and pitfalls of using old revived antibiotics to tackle the growing global threat of antimicrobial resistance.

The three day conference, ‘Reviving Old Antibiotics’ has attracted participation from almost 300 delegates from 45 countries. The expert panel and the delegates have identified and agreed a number of key actions which need to be taken urgently, if old antibiotics are to be used effectively:

To identify and gain consensus on candidates amongst old generations of antibiotics that are most needed to fight multi-drug resistant infections

  • For candidate antibiotics, to establish current quantities, global availability and dispersal, quality, appropriateness for human and non-human use, and to carry out the necessary studies to fill the knowledge gaps
  • To engage in a co-ordinated effort to disseminate and communicate to all stakeholders – including governments, donors, academics, researchers, health professionals and the pharmaceutical industry – to build support and gain consensus on the need for rapid action on exploring the benefits of using off-patent antibiotics to tackle antimicrobial resistance.


Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G. Reviving old antibiotics. J Antimicrob Chemother. 2015 Aug;70(8):2177-81.

Theuretzbacher U, Paul M.:Revival of old antibiotics: structuring the re-development process to optimize usage. Clin Microbiol Infect. 2015 Oct;21(10):878-80.

Muller AE, Theuretzbacher U, Mouton JW.: Use of old antibiotics now and in the future from a pharmacokinetic/pharmacodynamic perspective. Clin Microbiol Infect. 2015 Oct;21(10):881-5.

Old Antibiotics Course

Improving the Dosage of Old Antibiotics

AIDA together with the ESCMID PK/PD of Anti-Infectives Study Group (EPASG) organises and presents the Postgraduate Education Course on Improving the Dosage of Old Antibiotics on 19-21 November 2015 in Warsaw, Poland.

Course Objectives: This course presents and summarizes currently available knowledge regarding optimized clinical use of revived old antibiotics such as colistin, fosfomycin, temocillin, pivmecillinam, nitrofurantoin, fusidic acid, minocycline. The aim is to provide participants with an updated insight into clinical PK/PD concepts, improved dosage regimens, combinations, appropriate indications as a
key contribution to preserving the efficacy of these essential drugs in an era of escalating multi-drug resistance.

Course Venue: Hotel Bristol
Krakowskie Przedmiescie 42/44
00325 Warsaw, Poland

Faculty Members:
Karen Bowker, Bristol, United Kingdom Angela Huttner, Geneva, Switzerland
Yehuda Carmeli, Tel Aviv, Israel Leonard Leibovici, Petah-Tiqva, Israel
William Couet, Poitiers, France Alasdair MacGowan, Bristol, United Kingdom
Lena Friberg, Uppsala, Sweden Johan Mouton, Rotterdam, Netherlands
Niels Frimodt-Möller, Copenhagen, Denmark Anouk Muller, The Hague, Netherlands
Maciek Godycki-Cwirko, Lodz, Poland Mical Paul, Haifa, Israel
William Hope, Liverpool, United Kingdom Ursula Theuretzbacher, Vienna, Austria

fotos sm


Thursday, 19 November 2015

14:30-15:00 Welcome and introduction Ursula Theuretzbacher
15.00-15.30 Why do we need to revive old antibiotics? Ursula Theuretzbacher
15.30-16.30 Basics of optimal dosing Johan Mouton
16.30-17.00 Break
17.00-19.00 Dosing considerations for old antibiotics (e.g. colistin) and therapeutic drug monitoring Lena Friberg & William Couet
19.30 Dinner

Friday, 20 November 2015

9.00-9.30 Emergence of resistance in individual patients Yehuda Carmeli
9.30-10.00 Safety concerns and their relation to dosing Alasdair MacGowan
10.00-10.30 Reviving old antibiotics: the AIDA experience-preserving old antibiotics for the future Ursula Theuretzbacher
10.30-11.00 Coffee break
11.00-11.45 Integration of dosing into stewardship programmes (interactive) Mical Paul
11.45-13.00 Interpretation of clinical trial results (clinical case studies, interactive) Mical Paul, Leonard Leibovici
13.00 Lunch
14:00-14.30 What do we know about nitrofurantoin? Anouk Muller
14:30-15.00 What do we know about fosfomycin? Angela Huttner
15:00-15.30 What do we know about minocyclin? Karen Bowker
15:30-16.00 Break
16:00-17:30 How to optimize the use of oral antibiotics: nitrofurantoin, fosfomycin-trometamol, mecillinam, rifampicin, minocycline and other antibiotics (clinical case studies, interactive). A. Muller, W. Hope, N. Frimodt-Möller, A. Huttner, A. MacGowan & M. Godycki-Cwirko
17:30 Quiz with A. Muller, W. Hope, N. Frimodt-Möller, A. Hutter, A. MacGowan, M. Godycki-Cwirko
19:30 Dinner

Saturday, 21 November 2015

9:00-9:40 The clinical use of colistin: past, present, future Mical Paul
09:40-10:20 How to set breakpoints of old antibiotics: the EUCAST approach (interactive) MacGowan
10:20-11:00 Dosing in special patient populations William Hope
11:00-11:30 Break
11:30-12:30 Tools to support dosing decisions (case presentation, interactive) William Hope
12:30-13:30 How to optimize the use of i.v. antibiotics: Colistin, ß-lactams and other old antibiotics (clinical case studies, interactive). William Couet, Alasdair MacGowan
13:30 Closure
13:35 Lunch
%d bloggers like this: